AI Agents Design Novel Nanobodies

The "Virtual Lab" that designed these nanobodies was a coordinated team of Large Language Model (LLM) agents, each with a specific scientific role. A "principal investigator" agent set the research agenda, while specialist agents for immunology, machine learning, and biology executed tasks, and a "scientific critic" agent performed error checking and logical verification to refine the strategy. This multi-agent system mirrors a human interdisciplinary research team, but one that can design, test, and refine *in silico* in a matter of days. This agent-driven workflow relied on a sophisticated computational pipeline, starting with known nanobody scaffolds like Ty1 and Nb21. The agents used the ESM protein language model to evaluate mutations, AlphaFold-Multimer to predict the 3D structure of the resulting candidates, and Rosetta to refine their energetic stability and binding affinity. This process allowed for the rapid screening of a vast sequence space, leading to the 92 candidates selected for wet-lab validation. For a CDMO, implementing such an AI-driven workflow requires a robust, AI-ready data foundation. This means moving beyond siloed systems to a unified data architecture where R&D and manufacturing data are harmonized. A modern Laboratory Information Management System (LIMS) is critical, not just for storage, but for enforcing metadata standards and ensuring that data from high-throughput screening and automation platforms are clean, structured, and immediately usable for training AI models. The output of this AI design phase serves as the direct input for creating a bioprocess digital twin. The AI-defined molecular structure and predicted biophysical properties inform the initial parameters for a virtual model of the upstream and downstream manufacturing processes. This digital twin can then be used to simulate and optimize cell culture conditions and purification strategies *in silico*, significantly reducing the number of costly and time-consuming physical experiments needed for process development. From a regulatory standpoint, every step of this AI-driven process must be documented for GMP compliance. The design choices, model versions, and data sets used by the AI agents become part of the electronic batch record (EBR). For complex products like viral vectors and cell therapies, where a single batch can have over 3,000 data points, a validated EBR system is essential to ensure traceability from the *in silico* design to the final product. This shift towards agentic AI is set to transform the CDMO value proposition, moving from a fee-for-service model to becoming an "intelligent partner." CDMOs that build the infrastructure to support these AI-human collaborations can offer clients accelerated development timelines and more robust manufacturing processes. This involves not just adopting the AI tools, but also building the data governance, MLOps, and automation backbone required to connect AI-driven discovery with GMP-compliant manufacturing.